Prof. Dr. Konstanze Döhner - The Practicalities of Personalised Therapy in AML: The Who, How, When, and Why of Treating IDH1-Mutated Disease
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Prof. Dr. Konstanze Döhner - The Practicalities of Personalised Therapy in AML: The Who, How, When, and Why of Treating IDH1-Mutated Disease
-
ナレーター：
-
著者：
このコンテンツについて
For the full presentation, downloadable Practice Aids, slides, and complete EBAH/CME information, and to apply for credit, please visit us at PeerView.com/BNE865. EBAH/CME credit will be available until November 25, 2026.
The Practicalities of Personalised Therapy in AML: The Who, How, When, and Why of Treating IDH1-Mutated Disease
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an educational grant from Servier.
Disclosure information is available at the beginning of the video presentation.